Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences | PharmExec
Novartis Acquires Avidity Biosciences Novartis has entered a $12 billion definitive merger agreement to acquire Avidity Biosciences, enhancing its RNA therapeutics pipeline for rare neurom…